Key result
Journal masthead contains no clinical study data.
Why the study?
Cancer-associated thrombosis remains a major clinical challenge with complex pathophysiology, and limitations persist regarding the widespread use of direct oral anticoagulants despite recent advances.
Are direct oral anticoagulants effective and safe for the treatment and prevention of cancer-associated thrombosis compared to low-molecular-weight heparin?
Design
Review
Authors
Loading...
Offers no data to guide DOAC use in cancer thrombosis; leaves open comparative effectiveness versus LMWH.
Are direct oral anticoagulants effective and safe for the treatment and prevention of cancer-associated thrombosis compared to low-molecular-weight heparin?
This review highlights that DOACs are a noninferior alternative to LMWH for managing cancer-associated thrombosis, while noting important considerations like bleeding risk and drug interactions.
Dhami et al. (2021) studied this question. This document is a journal masthead and does not contain clinical study data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: